Rohto Pharmaceutical Co.,Ltd.
4527
株式のランク
#3845
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global... Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
株価
$19.13
時価総額
$4.32B
変化（1日）
0.64%
変化（1年）
16.90%
国
JP
取引 Rohto Pharmaceutical Co.,Ltd. (4527)
カテゴリー
Consumer Defensive
Rohto Pharmaceutical Co.,Ltd.（4527）の収益
Jun 2026 時点の収益 TTM: $2.31B
Rohto Pharmaceutical Co.,Ltd. の最新の財務報告によると、現在の収益 (TTM) は $2.31B です。2024 年には $1.79B の収益があり、これは 2023 年の $1.80B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Rohto Pharmaceutical Co.,Ltd. の収益履歴（2008 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $2.31B | 11.98% |
| 2025 | $2.06B | 15.06% |
| 2024 | $1.79B | -0.45% |
| 2023 | $1.80B | 9.63% |
| 2022 | $1.64B | 0.31% |
| 2021 | $1.63B | -6.70% |
| 2020 | $1.75B | 5.89% |
| 2019 | $1.65B | 2.34% |
| 2018 | $1.62B | 16.49% |
| 2017 | $1.39B | -6.19% |
| 2016 | $1.48B | 16.76% |
| 2015 | $1.27B | -9.28% |
| 2014 | $1.40B | 2.31% |
| 2013 | $1.37B | -5.93% |
| 2012 | $1.45B | 4.39% |
| 2011 | $1.39B | 14.55% |
| 2010 | $1.21B | 8.00% |
| 2009 | $1.12B | 3.58% |
| 2008 | $1.09B | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $87.03B | 3,674.79% |
US
|
|
| $51.67B | 2,140.87% |
FR
|
|
| $21.05B | 812.82% |
US
|
|
| $7.28B | 215.96% |
IN
|
|
| $15.05B | 552.71% |
US
|
